Physicochemical characterization of pre-clinical samples of a bacteriophage therapy spray-on patch for the treatment of COVID-19-related pressure injury resistant infections

冠状病毒大流行使压力损伤成为焦点。压力伤害的发生率在患者和卫生专业人员中急剧上升。这是由于全球ICU入院人数增加，机械通气需求大幅增加，俯卧位治疗急性呼吸窘迫综合征的使用增加，以及个人防护设备和医疗器械的使用急剧增加。 易受机会性多药耐药感染（MDR）影响的压力损伤可导致治疗延迟、败血症、骨髓炎、截肢和死亡。对于位于COVID-19患者血管受限区域的MDR菌株感染，经常报告抗生素治疗失败和疗效降低。 抗生素治疗的替代或补充是使用噬菌体靶向细菌感染。在人类中施用阿托伐他汀需要适当的递送系统。 在生理条件下生产稳定、无毒的喷雾剂构成了将噬菌体安全翻译到临床的新方法。为此，我们将噬菌体混合物包封在基于氨基酸的生物可降解聚合物中，以在损伤部位长期递送药物。 于二零二零年与FDA举行了IND前会议，为Phagelux产品PL-03-BM建立全面的CMC和临床计划。在这个合作研究项目中，我们的目标是表征微胶囊化的工程和临床前批次，以澄清与CMC相关的问题，并进一步推进用于治疗和预防压疮伤口感染的整体药物开发计划PL-03-BM。

The cororonavirus pandemic has brought pressure injuries into sharp focus. The incidence of pressure injuries has dramatically risen amongst patients and health professionals alike. This is due by the global increase in ICU admissions, considerable rise in the need of mechanical ventilation, increased use of prone positioning to treat acute respiratory distress syndrome, and sharp increase in the use of personal protective equipment and medical devices. Pressure injuries susceptible to opportunistic multi-drug resistant infections (MDR) can result in delayed treatment, septicemia, osteomyelitis, amputation, and death. Failure and reduced efficacy of antibiotic treatment are frequently reported for MDR strains for infections located in areas of limited vascularization in COVID-19 patients. An alternative or supplement to antibiotic therapy is the use of bacteriophages to target bacterial infections. Administration of phages in humans requires an appropriate delivery system. The production of stable, non-toxic spray under physiological conditions constitutes a novel approach for the safe translation of bacteriophages to the clinic. To this end we encapsulated the bacteriophage cocktail in amino acid-based biodegradable polymers for a prolonged delivery of phages at the site of injury. A pre-IND meeting was held with the FDA in 2020 to establish a comprehensive CMC and clinical program for Phagelux product PL-03-BM. In this collaborative research project, we aim to characterize engineering and preclinical batches of microencapsulated phages in order to clarify issues related to CMC and further the overall drug development program PL-03-BM for the treatment and prevention of pressure ulcer wound infections.